GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (FRA:01P) » Definitions » EPS (Diluted)

Medpace Holdings (FRA:01P) EPS (Diluted) : €10.47 (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings EPS (Diluted)?

Medpace Holdings's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €2.71. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €10.47.

Medpace Holdings's EPS (Basic) for the three months ended in Sep. 2024 was €2.80. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was €10.84.

Medpace Holdings's EPS without NRI for the three months ended in Sep. 2024 was €2.71. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €10.47.

During the past 12 months, Medpace Holdings's average EPS without NRIGrowth Rate was 33.70% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 32.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Medpace Holdings's highest 3-Year average EPS without NRI Growth Rate was 68.50% per year. The lowest was -7.80% per year. And the median was 36.55% per year.


Medpace Holdings EPS (Diluted) Historical Data

The historical data trend for Medpace Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings EPS (Diluted) Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 3.16 4.26 6.87 8.14

Medpace Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 2.26 2.94 2.56 2.71

Competitive Comparison of Medpace Holdings's EPS (Diluted)

For the Diagnostics & Research subindustry, Medpace Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's PE Ratio falls into.



Medpace Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Medpace Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(259.337-0)/31.841
=8.14

Medpace Holdings's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(86.88-0)/32.088
=2.71

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings  (FRA:01P) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Medpace Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Medpace Holdings Headlines

No Headlines